Sars-cov-2 vaccines
US-2024408193-A1 · Dec 12, 2024 · US
Virus-like particles (VLPs) prepared from chikungunya virus structural proteins
US9353353B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9353353-B2 |
| Application number | US-200913131287-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 24, 2009 |
| Priority date | Nov 26, 2008 |
| Publication date | May 31, 2016 |
| Grant date | May 31, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.
First claim
Opening claim text (preview).
What is claimed is: 1. A virus-like particle (VLP) comprising one or more Chikungunya virus structural polypeptides, wherein the one or more virus structural proteins are from Chikungunya virus strain 37997, and wherein the VLP does not early genetic information encoding the VLP proteins. 2. The VLP of claim 1 , wherein the structural polypeptides are selected from the group consisting of capsid (C) and envelope proteins E3, E2, 6K and E1. 3. The VLP of claim 1 , wherein the VLP comprises envelope proteins E3, E2, 6K and E1. 4. The VLP of claim 1 , wherein the VLP comprises a polyprotein comprising C-E3-E2-6K-E1. 5. An immunogenic composition comprising an effective amount of a virus-like particle of claim 1 . 6. The immunogenic composition of claim 5 , further comprising an adjuvant. 7. The immunogenic composition of claim 5 , wherein the VLP induces antibodies against homologous or heterologous strains of Chikungunya. 8. The immunogenic composition of claim 6 , wherein the adjuvant is an immunostimulating agent. 9. The immunogenic composition of claim 6 , wherein the adjuvant is selected from the group consisting of Ribi, aluminum salts, muramyl peptides, bacterial cell wall components, and saponin adjuvants.
Assignees
Inventors
Classifications
Antivirals · CPC title
for RNA viruses · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Virus-like particles · CPC title
- A61K39/12Primary
Viral antigens · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9353353B2 cover?
- The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.
- Who is the assignee on this patent?
- Nabel Gary J, Akahata Wataru, Rao Srinivas, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).